Biosyent (CVE:RX) released its quarterly earnings data on Wednesday. The company reported C$0.09 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.12 by C($0.03), Morningstar.com reports. The firm had revenue of C$5.26 million during the quarter, compared to analysts’ expectations of C$6.48 million.
CVE:RX opened at C$7.15 on Friday. Biosyent has a 12 month low of C$6.93 and a 12 month high of C$10.50.
Separately, Raymond James dropped their price objective on Biosyent from C$12.50 to C$11.00 and set an “outperform” rating for the company in a research note on Thursday.
Biosyent Company Profile
BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.
Read More: Asset Allocation and Your Retirement
Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.